Horjen Anja Wiedswang, Seljeflot Ingebjørg, Berge Trygve, Smith Pål, Arnesen Harald, Tveit Arnljot
Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, N-3004 Drammen, Norway.
Faculty of Medicine, University of Oslo, Oslo, Norway.
Thromb J. 2017 Dec 28;15:30. doi: 10.1186/s12959-017-0153-1. eCollection 2017.
Atrial fibrillation (AF) confers a hypercoagulable state; however, it is not clear whether restoration of sinus rhythm is associated with normalisation of markers of thrombogenesis. We studied the impact of sustained sinus rhythm on prothrombotic markers, and their predictive abilities in foreseeing rhythm outcome after cardioversion.
In a double blind, placebo-controlled study, 171 patients referred for electrical cardioversion of persistent AF were randomised to receive candesartan or placebo for 3-6 weeks before and 6 months after cardioversion. Endogenous thrombin potential (ETP), prothrombin fragment 1 + 2 (F1 + 2) and D-dimer were measured before cardioversion and at end of study. These markers were also measured in a reference group comprising 49 subjects without AF.
The markers remained unchanged in those 28 patients who maintained sinus rhythm. Discontinuation of warfarin treatment in a subset of 13 low-risk patients in sinus rhythm was associated with significantly higher levels of D-dimer and F1 + 2 compared to the reference group; D-dimer (456 ng/mL (276, 763) vs. 279 ng/mL (192, 348), = 0.002) and F1 + 2 (700 pmol/L (345, 845) vs. 232 pmol/L (190, 281), < 0.001). None of the markers were associated with rhythm outcome after electrical cardioversion.
Sustained sinus rhythm for 6 months after cardioversion for AF had no impact on ETP, F1 + 2 or D-dimer levels. Discontinuation of warfarin in low-risk patients with sustained sinus rhythm was associated with significantly higher levels of D-dimer and F1 + 2 compared to the reference group. Our results suggest persistent hypercoagulability in AF patients despite long-term maintenance of sinus rhythm.
The CAPRAF study was registered at clinicaltrials.gov (NCT00130975) in August 2005.
心房颤动(AF)会导致血液高凝状态;然而,目前尚不清楚恢复窦性心律是否与血栓形成标志物的正常化相关。我们研究了持续性窦性心律对血栓前标志物的影响,以及它们在预测心脏复律后心律转归方面的能力。
在一项双盲、安慰剂对照研究中,171例因持续性房颤接受电复律的患者被随机分组,在复律前3 - 6周及复律后6个月接受坎地沙坦或安慰剂治疗。在复律前及研究结束时测量内源性凝血酶潜能(ETP)、凝血酶原片段1 + 2(F1 + 2)和D - 二聚体。这些标志物也在一个由49名无房颤受试者组成的参照组中进行测量。
在28例维持窦性心律的患者中,这些标志物保持不变。与参照组相比,13例窦性心律的低风险患者亚组停用华法林治疗后,D - 二聚体和F1 + 2水平显著升高;D - 二聚体(456 ng/mL(276, 763)对279 ng/mL(192, 348),P = 0.002)和F1 + 2(700 pmol/L(345, 845)对232 pmol/L(190, 281),P < 0.001)。电复律后,没有一个标志物与心律转归相关。
房颤复律后6个月的持续性窦性心律对ETP、F1 + 2或D - 二聚体水平没有影响。与参照组相比,窦性心律持续的低风险患者停用华法林后,D - 二聚体和F1 + 2水平显著升高。我们的结果表明,尽管长期维持窦性心律,但房颤患者仍存在持续性高凝状态。
CAPRAF研究于2005年8月在clinicaltrials.gov(NCT00130975)注册。